Ambit Biosciences Corporation Gets $5 Million With Expanded Bristol-Myers Squibb Company Deal

/27/2006 – Drug discovery and development company Ambit Biosciences Corp. received a $5 million equity investment from Bristol-Myers Squibb Co. late last month as a result of an expanded kinase inhibitor collaboration with the pharmaceutical giant, Chief Executive Scott Salka told VentureWire. [ full story ]

Back to news